Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study

Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients

(2019) Manuel Camean-Castillo et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Opuntioside, opuntiol and its metallic nanoparticles attenuate adjuvant-induced arthritis: Novel suppressors of Toll-like receptors -2 and -4

(2019) Talat Roome et al.   BIOMEDICINE & PHARMACOTHERAPY

Linear and Rationally Designed Stapled Peptides Abrogate TLR4 Pathway and Relieve Inflammatory Symptoms in Rheumatoid Arthritis Rat Model

(2019) Asma Achek et al.   JOURNAL OF MEDICINAL CHEMISTRY

Levetiracetam mitigates lipopolysaccharide-induced JAK2/STAT3 and TLR4/MAPK signaling pathways activation in a rat model of adjuvant- induced arthritis

(2018) Omnia Ahmed Mohamed Abed El-Gaphar et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Redox-active trace metal-induced release of high mobility group box 1(HMGB1) and inflammatory cytokines in fibroblast-like synovial cells is Toll-like receptor 4 (TLR4) dependent

(2018) Asmaa A. Alsousi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Direct recognition of LPS drive TLR4 expressing CD8+ T cell activation in patients with rheumatoid arthritis

(2017) Archana Tripathy et al.   Scientific Reports

Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS

(2016) E Monnet et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Spatiotemporal expression of endogenous TLR4 ligands leads to inflammation and bone erosion in mouse collagen-induced arthritis

(2016) Gaëlle Wambiekele Kiyeko et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Granulocyte-augmented chemokine production induced by type II collagen containing immune complexes is mediated via TLR4 in rheumatoid arthritis patients

(2016) Vivek Anand Manivel et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study

(2016) Josef S Smolen et al.   LANCET

Hyaluronan Inhibits Tlr-4-Dependent RANKL Expression in Human Rheumatoid Arthritis Synovial Fibroblasts

(2016) Tatsuo Watanabe et al.   PLoS One

Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled tri

(2015) Young Ho Lee et al.   International Journal of Rheumatic Diseases

IgM and IgA Rheumatoid Factors Purified from Rheumatoid Arthritis Sera Boost the Fc Receptor– and Complement-Dependent Effector Functions of the Disease-Specific Anti–Citrullinated Protein Autoantibodies

(2015) Florence Anquetil et al.   JOURNAL OF IMMUNOLOGY

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis

(2015) Mark C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review

(2015) T. M. Kuijper et al.   JOURNAL OF RHEUMATOLOGY

Local Joint Inflammation and Histone Citrullination in a Murine Model of the Transition From Preclinical Autoimmunity to Inflammatory Arthritis

(2015) Dong Hyun Sohn et al.   Arthritis & Rheumatology

Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial

(2013) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Lipopolysaccharide Activates Toll-like Receptor 4 (TLR4)-mediated NF-κB Signaling Pathway and Proinflammatory Response in Human Pericytes

(2013) Irene Guijarro-Muñoz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of cartilage impact with and without fracture on chondrocyte viability and the release of inflammatory markers

(2013) Josef A. Stolberg-Stolberg et al.   JOURNAL OF ORTHOPAEDIC RESEARCH

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis

(2011) F. G. Goh et al.   RHEUMATOLOGY

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

(2010) Todd W. Rice et al.   CRITICAL CARE MEDICINE

The Inhibitory Fc IIb Receptor Dampens TLR4-Mediated Immune Responses and Is Selectively Up-regulated on Dendritic Cells from Rheumatoid Arthritis Patients with Quiescent Disease

(2009) M. H. Wenink et al.   JOURNAL OF IMMUNOLOGY

The role of Toll-like receptors in rheumatoid arthritis

(2009) Qi-Quan Huang et al.   Current Rheumatology Reports

Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis

(2008) Caroline Ospelt et al.   ARTHRITIS AND RHEUMATISM